DOP2014000175A - Inhibidores de pde9 con estructura básica de imidazotriazinona - Google Patents
Inhibidores de pde9 con estructura básica de imidazotriazinonaInfo
- Publication number
- DOP2014000175A DOP2014000175A DO2014000175A DO2014000175A DOP2014000175A DO P2014000175 A DOP2014000175 A DO P2014000175A DO 2014000175 A DO2014000175 A DO 2014000175A DO 2014000175 A DO2014000175 A DO 2014000175A DO P2014000175 A DOP2014000175 A DO P2014000175A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compound
- formula
- effective amount
- therapeutically effective
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a compuestos, que son inhibidores de la enzima PDE9. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención también proporciona procesos para preparar compuestos de fórmula (I). La presente invención proporciona además un método para tratar un sujeto que padece un trastorno neurodegenerativo que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula (I). La presente invención proporciona además un compuesto de fórmula (I) para su uso en un método para tratar un sujeto que padece un trastorno psiquiátrico que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula (I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012070718 | 2012-01-26 | ||
| CN2012080208 | 2012-08-16 | ||
| PCT/EP2013/051451 WO2013110768A1 (en) | 2012-01-26 | 2013-01-25 | Pde9 inhibitors with imidazo triazinone backbone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2014000175A true DOP2014000175A (es) | 2014-08-31 |
Family
ID=47603775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2014000175A DOP2014000175A (es) | 2012-01-26 | 2014-07-25 | Inhibidores de pde9 con estructura básica de imidazotriazinona |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9434733B2 (es) |
| EP (2) | EP3178820B1 (es) |
| CN (2) | CN107082783B (es) |
| AP (1) | AP2014007820A0 (es) |
| AU (2) | AU2013213603B2 (es) |
| BR (1) | BR112014018199A8 (es) |
| CO (1) | CO7020913A2 (es) |
| CR (1) | CR20140361A (es) |
| DO (1) | DOP2014000175A (es) |
| EC (1) | ECSP14015609A (es) |
| HK (1) | HK1199879A1 (es) |
| MX (1) | MX351582B (es) |
| PH (1) | PH12014501695A1 (es) |
| SG (1) | SG11201403909RA (es) |
| WO (1) | WO2013110768A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2619208T3 (pl) | 2010-09-20 | 2017-03-31 | Ironwood Pharmaceuticals, Inc. | Związki imidazotriazynonu |
| EP3406287B1 (en) | 2010-10-08 | 2022-04-27 | Fisher & Paykel Healthcare Limited | Respiratory mask assembly for breathing assistance apparatus |
| EP3121178B1 (en) | 2011-10-10 | 2018-09-19 | H. Lundbeck A/S | 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor |
| US9434733B2 (en) | 2012-01-26 | 2016-09-06 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone |
| WO2013142269A1 (en) | 2012-03-19 | 2013-09-26 | Envivo Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| WO2016006975A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |
| KR20160007347A (ko) | 2014-07-11 | 2016-01-20 | 에스티팜 주식회사 | 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도 |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| WO2017000276A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| ES2971969T3 (es) | 2015-07-07 | 2024-06-10 | H Lundbeck As | Inhibidores de PDE9 con cadena principal de imidazopirazinona para el tratamiento de enfermedades periféricas |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| CN109475556A (zh) | 2016-07-06 | 2019-03-15 | 伊马拉公司 | 用于治疗外周疾病的pde9抑制剂 |
| JP7112413B2 (ja) | 2016-10-18 | 2022-08-03 | ハー・ルンドベック・アクチエゼルスカベット | Ｐｄｅ１阻害剤としてのイミダゾピラジノン、ピラゾロピリミジノンおよびピラゾロピリジノン |
| PL3532064T3 (pl) | 2016-10-28 | 2020-11-16 | H. Lundbeck A/S | Terapie skojarzone obejmujące imidazopirazynony do leczenia zaburzeń psychiatrycznych i/lub poznawczych |
| AU2017350477A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| PT3541784T (pt) * | 2016-11-18 | 2023-11-22 | Integrative Res Laboratories Sweden Ab | Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical |
| CN110325193B (zh) * | 2017-02-23 | 2023-05-05 | 勃林格殷格翰国际有限公司 | 化合物iii的新型医学用途 |
| US11370795B2 (en) * | 2017-05-26 | 2022-06-28 | Imara Inc. | Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one |
| CN110003213B (zh) * | 2018-01-04 | 2021-10-08 | 南京农业大学 | 苯并咪唑并三嗪酮类化合物、制备方法及应用 |
| WO2019136157A2 (en) | 2018-01-05 | 2019-07-11 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and ido expression to potentiate immunotherapy |
| HRP20240363T1 (hr) | 2018-05-25 | 2024-06-07 | Cardurion Pharmaceuticals, Inc. | Monohidratni i kristalni oblici 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a] pirazin-8-ona |
| WO2020227399A1 (en) * | 2019-05-07 | 2020-11-12 | Imara Inc. | Pde9 inhibitors for treating thalassemia |
| CN113072556B (zh) * | 2021-03-30 | 2022-02-01 | 牡丹江医学院 | 一种用于治疗胶质瘤的药物及其制备方法 |
| WO2024107445A1 (en) * | 2022-11-15 | 2024-05-23 | Freedom Biosciences, Inc. | Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2295436A1 (de) | 1997-11-12 | 2011-03-16 | Bayer Schering Pharma AG | 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren |
| HUP0105132A3 (en) | 1999-01-20 | 2002-12-28 | Dresden Arzneimittel | Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions |
| CN1575191A (zh) | 2001-11-02 | 2005-02-02 | 辉瑞产品公司 | 用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病 |
| HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| GB2388111A (en) | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
| US6684626B1 (en) | 2002-07-30 | 2004-02-03 | General Electric Company | Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines |
| US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| BRPI0416118A (pt) | 2003-10-31 | 2007-01-02 | Pfizer Prod Inc | inibição da fosfodiesterase 9 como tratamento para estados relacionados com a obesidade |
| TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| KR101563103B1 (ko) | 2006-12-13 | 2015-10-23 | 아스카 세이야쿠 가부시키가이샤 | 퀴녹살린 유도체 |
| PL2152712T3 (pl) * | 2007-05-11 | 2012-05-31 | Pfizer | Związki aminoheterocykliczne |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| WO2009076387A1 (en) | 2007-12-10 | 2009-06-18 | Glaxo Group Limited | Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| EP2456311A4 (en) | 2009-07-24 | 2013-01-23 | Concert Pharmaceuticals Inc | SUBSTITUTED IMIDASOTRIAZINES |
| WO2011028820A1 (en) | 2009-09-02 | 2011-03-10 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
| PL2619208T3 (pl) | 2010-09-20 | 2017-03-31 | Ironwood Pharmaceuticals, Inc. | Związki imidazotriazynonu |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| US9434733B2 (en) * | 2012-01-26 | 2016-09-06 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone |
-
2013
- 2013-01-25 US US14/374,278 patent/US9434733B2/en active Active
- 2013-01-25 CN CN201710176546.6A patent/CN107082783B/zh active Active
- 2013-01-25 BR BR112014018199A patent/BR112014018199A8/pt active Search and Examination
- 2013-01-25 AP AP2014007820A patent/AP2014007820A0/xx unknown
- 2013-01-25 EP EP17152165.1A patent/EP3178820B1/en active Active
- 2013-01-25 MX MX2014008912A patent/MX351582B/es active IP Right Grant
- 2013-01-25 EP EP13701270.4A patent/EP2807163B1/en active Active
- 2013-01-25 AU AU2013213603A patent/AU2013213603B2/en active Active
- 2013-01-25 WO PCT/EP2013/051451 patent/WO2013110768A1/en active Application Filing
- 2013-01-25 CN CN201380006255.2A patent/CN104093720B/zh active Active
- 2013-01-25 SG SG11201403909RA patent/SG11201403909RA/en unknown
-
2014
- 2014-07-24 CR CR20140361A patent/CR20140361A/es unknown
- 2014-07-24 CO CO14161415A patent/CO7020913A2/es unknown
- 2014-07-25 PH PH12014501695A patent/PH12014501695A1/en unknown
- 2014-07-25 DO DO2014000175A patent/DOP2014000175A/es unknown
- 2014-08-25 EC ECIEPI201415609A patent/ECSP14015609A/es unknown
-
2015
- 2015-01-13 HK HK15100346.4A patent/HK1199879A1/xx unknown
-
2016
- 2016-04-04 US US15/089,819 patent/US9533992B2/en active Active
- 2016-11-22 US US15/358,168 patent/US9850249B2/en active Active - Reinstated
-
2017
- 2017-02-09 AU AU2017200886A patent/AU2017200886B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014501695B1 (en) | 2014-10-20 |
| AU2017200886A1 (en) | 2017-03-02 |
| US9533992B2 (en) | 2017-01-03 |
| AU2013213603A1 (en) | 2014-07-24 |
| EP3178820B1 (en) | 2017-12-20 |
| WO2013110768A1 (en) | 2013-08-01 |
| CN104093720B (zh) | 2017-04-12 |
| MX351582B (es) | 2017-10-20 |
| CN104093720A (zh) | 2014-10-08 |
| US9850249B2 (en) | 2017-12-26 |
| EP3178820A1 (en) | 2017-06-14 |
| US9434733B2 (en) | 2016-09-06 |
| CO7020913A2 (es) | 2014-08-11 |
| US20160213674A1 (en) | 2016-07-28 |
| AP2014007820A0 (en) | 2014-07-31 |
| MX2014008912A (es) | 2014-08-26 |
| ECSP14015609A (es) | 2015-12-31 |
| HK1199879A1 (en) | 2015-07-24 |
| SG11201403909RA (en) | 2014-10-30 |
| BR112014018199A8 (pt) | 2021-03-02 |
| CR20140361A (es) | 2014-11-11 |
| CN107082783B (zh) | 2019-03-22 |
| US20150045348A1 (en) | 2015-02-12 |
| EP2807163A1 (en) | 2014-12-03 |
| AU2013213603B2 (en) | 2017-02-02 |
| EP2807163B1 (en) | 2017-03-22 |
| PH12014501695A1 (en) | 2014-10-20 |
| AU2017200886B2 (en) | 2018-01-18 |
| CN107082783A (zh) | 2017-08-22 |
| US20170081333A1 (en) | 2017-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2014000175A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
| IN2015DN02829A (es) | ||
| ECSP13012698A (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| CO6321263A2 (es) | Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a | |
| CR20120319A (es) | Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a | |
| DOP2012000168A (es) | Derivados de 2-arimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| DOP2012000169A (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a | |
| PH12015501980A1 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same | |
| DOP2014000141A (es) | Derivados de quinolina como inhibidores de la enzima pde10a | |
| DOP2013000108A (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| TN2014000288A1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
| CY1116689T1 (el) | Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a |